In a development that could rewrite the story of Type 1 diabetes, Vertex Pharmaceuticals has announced that a stem cell-based therapy has enabled people with the condition to produce their own insulin—sometimes for the first time in decades. This isn’t a new pump or wearable; it’s a treatment aimed at replacing what the immune system destroyed years ago. The results from a small trial are early, but they’re the most promising to date in what many still consider one of the most complex autoimmune conditions to treat.
In a Phase 1 clinical trial involving 12 adults with advanced Type 1 diabetes, participants received a single infusion of pancreatic islet-like cells grown from pluripotent stem cells. According to The New York Times, 10 out of the 12 patients were able to stop injecting insulin entirely within a year of treatment. All of them saw improvements in glucose control, and none experienced severe hypoglycaemia during the study period. That’s a striking result given the small sample size and the fact these were not newly diagnosed patients.
How the therapy works
Type 1 diabetes is caused by the immune system attacking insulin-producing beta cells in the pancreas. These are the very cells that regulate blood sugar by releasing insulin in response to glucose levels. Without them, people rely on regular insulin injections, carbohydrate counting, and careful glucose monitoring. While insulin delivery has improved, with smart pumps and continuous glucose monitors making management easier, the root problem has remained: the body no longer makes insulin on its own.
Vertex’s therapy involves growing replacement beta cells in the lab. These stem cells are coaxed into becoming islet-like cells—the same kind lost in Type 1 diabetes—and then injected under the patient’s skin. There, they settle and begin releasing insulin in response to blood sugar levels. Because these are not donor-derived but produced in bulk, the approach has the potential to be scalable. And crucially, it doesn’t require surgery.
This isn’t the only islet-based innovation showing promise. Earlier this year, another study, published in The British Medical Journal, found that genetically modified donor islet cells were producing insulin just 28 days after transplantation. The momentum around these therapies points to a sea change in how we understand and possibly treat this lifelong condition.
The implications—and the remaining questions
For those living with brittle or severe Type 1 diabetes, the appeal of such a therapy is obvious. Imagine no longer needing to calculate boluses before meals, no overnight alarms, no constant fear of a sudden drop in blood sugar. Vertex’s results show that insulin independence, even temporary, is now within reach for some patients.
But this is still a cautious celebration. The trial is small and early-stage, and the patients were selected carefully—they had a history of hypoglycaemic episodes and poor glucose control despite diligent care. That means it’s not clear yet how this would work in a broader population, or how durable the effects will be over the long term.
Then there’s the issue of immune rejection. Even though the cells are lab-grown, the immune system still sees them as foreign. That means patients currently need to take immunosuppressive drugs to prevent their bodies from attacking the new cells. These drugs come with risks, and researchers are actively exploring how to protect or cloak the islet cells so they can survive without constant immune suppression. Similar efforts have included encapsulating the cells in tiny biocompatible pouches or using gene editing to make them less detectable by the immune system.
There’s also the cost and logistics of production. Making stem cell therapies is complex and resource-intensive. It’s one thing to prove something works in a tightly controlled trial—it’s another to manufacture it consistently, safely, and affordably for widespread clinical use.
Still, what’s promising is that the concept is now proven in humans. This marks the first time an off-the-shelf stem cell therapy has restored insulin production to this degree in people with long-standing diabetes.
A step closer to changing daily life for millions
In the UK alone, there are an estimated 400,000 people living with Type 1 diabetes. Worldwide, that number runs into the millions. While many manage well with existing treatments, there’s a smaller group—those with so-called “brittle” diabetes—who experience dangerous highs and lows despite best efforts. For these patients, a therapy that returns the ability to make insulin is potentially life-changing.
This isn’t about replacing insulin for everyone just yet. It’s about finding options for people for whom traditional management isn’t enough. It also lays a foundation for future therapies that could become more refined, with fewer side effects and broader applications.
We’re still some way from this being offered routinely in clinics, but it’s not science fiction anymore. The technology is real, the results are measurable, and the vision of reducing or even ending the daily grind of insulin therapy is edging closer to reality. For now, it’s a glimpse of what could be, and that’s no small thing.